154 related articles for article (PubMed ID: 9311606)
1. Circumvention of glutathione-mediated mitomycin C resistance by a novel mitomycin C analogue, KW-2149.
Ishida T; Nishio K; Kurokawa H; Arioka H; Fukumoto H; Fukuoka K; Nomoto T; Yokote H; Hasegawa S; Saijo N
Int J Cancer; 1997 Sep; 72(5):865-70. PubMed ID: 9311606
[TBL] [Abstract][Full Text] [Related]
2. Nonenzymatic reductive activation of 7-N-((2-([2-(gamma-L-glutamylamino)ethyl]dithio)ethyl))mitomycin C by thiol molecules: a novel mitomycin C derivative effective on mitomycin C-resistant tumor cells.
Lee JH; Naito M; Tsuruo T
Cancer Res; 1994 May; 54(9):2398-403. PubMed ID: 8162587
[TBL] [Abstract][Full Text] [Related]
3. [gamma-Glutamylcysteine synthetase and chemosensitivity].
Nishio K; Kurokawa H; Ishida T; Fukuoka K; Saijo N
Gan To Kagaku Ryoho; 1997 Feb; 24(4):418-23. PubMed ID: 9063478
[TBL] [Abstract][Full Text] [Related]
4. 7-N-(2-([2-(gamma-L-glutamylamino)-ethyl]-dithio)-ethyl)-mitomycin C (KW-2149) is more active than mitomycin C on chemonaive and drug-resistant urothelial carcinoma cells.
Rohde D; Raffenberg G; Kaviani S; Wolff J; Jakse G
Urol Res; 1998; 26(4):243-7. PubMed ID: 9759997
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of 7-N-[[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]]-mitomycin C.
Morimoto M; Ashizawa T; Ohno H; Azuma M; Kobayashi E; Okabe M; Gomi K; Kono M; Saitoh Y; Kanda Y
Cancer Res; 1991 Jan; 51(1):110-5. PubMed ID: 1988076
[TBL] [Abstract][Full Text] [Related]
6. Modulation of sensitivity to mitomycin C and a dithiol analogue by tempol in non-small-cell lung cancer cell lines under hypoxia.
Bando T; Kasahara K; Shibata K; Numata Y; Heki U; Shirasaki H; Iwasa K; Fujimura M; Matsuda T
J Cancer Res Clin Oncol; 1996; 122(1):21-6. PubMed ID: 8543588
[TBL] [Abstract][Full Text] [Related]
7. Antitumor activity of a derivative of mitomycin, 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C (KW-2149), against murine and human tumors and a mitomycin C-resistant tumor in vitro and in vivo.
Tsuruo T; Sudo Y; Asami N; Inaba M; Morimoto M
Cancer Chemother Pharmacol; 1990; 27(2):89-93. PubMed ID: 2123421
[TBL] [Abstract][Full Text] [Related]
8. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl] mitomycin C): DNA interactions and drug uptake following serum activation.
McAdam SR; Knox RJ; Hartley JA; Masters JR
Biochem Pharmacol; 1998 Jun; 55(11):1777-83. PubMed ID: 9714295
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxic activity of 7-N-(2-((2-(-gamma-L-glutamylamino)- ethyl)dithio)ethyl)-mitomycin C and metabolites in cell lines with different resistance patterns.
Dirix LY; Gheuens EE; van der Heyden S; van Oosterom AT; De Bruijn EA
Anticancer Drugs; 1994 Jun; 5(3):343-54. PubMed ID: 7919460
[TBL] [Abstract][Full Text] [Related]
10. Comparison of uptake of mitomycin C and KW-2149 by murine P388 leukemia cells sensitive or resistant to mitomycin C.
Kobayashi E; Okabe M; Kono M; Arai H; Kasai M; Gomi K; Lee JH; Inaba M; Tsuruo T
Cancer Chemother Pharmacol; 1993; 32(1):20-4. PubMed ID: 8096440
[TBL] [Abstract][Full Text] [Related]
11. Characterization of a human bladder cancer cell line selected for resistance to BMY 25067, a novel analogue of mitomycin C.
Singh SV; Xu BH; Gupta V; Emerson EO; Zaren HA; Jani JP
Cancer Lett; 1995 Aug; 95(1-2):49-56. PubMed ID: 7656243
[TBL] [Abstract][Full Text] [Related]
12. KW-2149 (7-N-[2-[gamma-L-glutamylamino]ethyldithioethyl]mitomycin C). A new mitomycin C analogue activated by serum.
Masters JR; Know RJ; Hartley JA; Kelland LR; Hendriks HR; Connors T
Biochem Pharmacol; 1997 Feb; 53(3):279-85. PubMed ID: 9065731
[TBL] [Abstract][Full Text] [Related]
13. Comparative studies on the action of 7-N-[2-[[2-(gamma-L-glutamylamino)ethyl]dithio]ethyl]mitomycin C and of mitomycin C on cultured HL-60 cells and isolated phage and plasmid DNA.
Ishioka C; Kanamaru R; Konishi Y; Ishikawa A; Shibata H; Wakui A
Cancer Chemother Pharmacol; 1990; 26(2):117-21. PubMed ID: 2112051
[TBL] [Abstract][Full Text] [Related]
14. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
[TBL] [Abstract][Full Text] [Related]
15. Characteristics of the antitumor activity of M-16 and M-18, major metabolites of a new mitomycin C derivative KW-2149, in mice.
Ashizawa T; Okamoto A; Okabe M; Kobayashi S; Arai H; Saito H; Kasai M; Gomi K
Anticancer Drugs; 1995 Dec; 6(6):763-70. PubMed ID: 8845489
[TBL] [Abstract][Full Text] [Related]
16. Biochemical characterization of a mitomycin C-resistant human bladder cancer cell line.
Singh SV; Scalamogna D; Xia H; O'Toole S; Roy D; Emerson EO; Gupta V; Zaren HA
Int J Cancer; 1996 Mar; 65(6):852-7. PubMed ID: 8631603
[TBL] [Abstract][Full Text] [Related]
17. The influence of hypoxia on the cytotoxicity of concomitant KW-2149 and ionizing irradiation in Chinese hamster fibroblasts.
Egelmeers A; Dirix LY; Lyczek J; De Bruijn EA; Van Oosterom AT; Scalliet P
Anticancer Drugs; 1996 Jul; 7(5):586-90. PubMed ID: 8862727
[TBL] [Abstract][Full Text] [Related]
18. Lack of a role of glutathione in cellular nonenzymatic activation of BMS-181174, a novel analogue of mitomycin C.
Xia H; Pinto T; Hu X; Benson PJ; Zaren HA; Gupta V; Singh S
Cancer Res; 1996 Aug; 56(15):3495-8. PubMed ID: 8758917
[TBL] [Abstract][Full Text] [Related]
19. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines.
Lambert PA; Kang Y; Greaves B; Perry RR
J Surg Res; 1998 Dec; 80(2):177-81. PubMed ID: 9878310
[TBL] [Abstract][Full Text] [Related]
20. Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins.
Iida T; Kijima H; Urata Y; Goto S; Ihara Y; Oka M; Kohno S; Scanlon KJ; Kondo T
Cancer Gene Ther; 2001 Oct; 8(10):803-14. PubMed ID: 11687904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
